AP

General Information


DRACP ID  DRACP00233

Peptide Name   AP

Sequence  ACDCRGDCFCGGGGIVRRADRAAVP

Sequence Length  25

UniProt ID  Not available

PubChem CID  Not available

Origin  Endostatin derived Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
B16-F10 Mouse melanoma Carcinoma 50% inhibition at 2.5µg/ml MTT assay 72 h 1
B16-F10 Mouse melanoma Carcinoma 40% inhibition at 5µg/ml MTT assay 72 h 1
B16-F10 Mouse melanoma Carcinoma 75% inhibition at 10µg/ml MTT assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  integrin αvβ3

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00233

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C100H165N37O32S4

Absent amino acids  EHKLMNQSTWY

Common amino acids  G

Mass  295418

Pl  7.92

Basic residues  4

Acidic residues  3

Hydrophobic residues  8

Net charge  1

Boman Index  -5280

Hydrophobicity  3.2

Aliphatic Index  54.8

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  250

Absorbance 280nm  10.42

Polar residues  9

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 20515045

Title  Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide

Doi 10.1021/bc900292y

Year  2010

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.